Chao Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Liang has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Junmei Wu
11 shared publicationsChengyu Wang
8 shared publicationsJingyi Wu
7 shared publicationsYimei Lin
7 shared publicationsChanghong Miao
6 shared publications- Changhong Miao
Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
6 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Elsevier in SSRN Electronic Journal
Interpretable Deep Learning for Comprehensive Cardiac Risk Stratification after Esophageal Cancer Surgery: Development and External Validation of the InterpretabNet Model for Myocardial Injury and New-Onset Atrial Fibrillation
Background: Myocardial injury after non-cardiac surgery (MINS) and new-onset postoperative atrial fibrillation (POAF) are common and serious complications. We developed and externally validated an interpretable machine-learning platform (InterpretabNet) to predict MINS and POAF in patients recovering oesophageal cancer surgery.Methods: We retrospectively included 3,573 adults who underwent elective oesophagectomy for oesophageal cancer at Zhongshan Hospital, Fudan University, Shanghai, China, between 1 January 2015 and 30 June 2025. The cohort was divided using a fixed stratified 80:20 split into a training cohort of 2,858 patients and an internal validation cohort of 715 patients. External validation was performed in 638 eligible patients from the INSPIRE database, comprising patients treated at Seoul National University Hospital, Seoul, Republic of Korea, between 2011 and 2020. MINS was defined as an ischaemic postoperative cardiac troponin elevation above the assay-specific 99th-percentile upper reference limit occurring within the first 72 h after surgery. New-onset POAF was defined as an atrial fibrillation episode lasting ≥30 s or requiring treatment and detected during the first 7 postoperative days or until hospital discharge, whichever occurred first. InterpretabNet was compared with extreme gradient boosting, random forest, support vector machine, decision tree, and penalised logistic regression.ResultsPOAF was observed in 28% of the patients in the derivation cohort, and MINS in 30%. Interpretation: Net showed high discrimination in internal validation (POAF AUC 0.933 [95%CI: 0.916-0.951]; MINS AUC 0.933 [95%CI: 0.916-0.951]) and in the external cohort (POAF AUC 0.939 [95%CI: 0.922-0.956]; MINS AUC 0.936 [95%CI: 0.917-0.955]), with balanced sensitivity and specificity and good calibration. SHAP analyses identified similar risk factors for both endpoints, dominated by age, hypertension, diabetes, BMI, obstructive sleep apnoea, pre-operative haemoglobin, surgical duration, inflammatory markers, and blood loss. Decision-curve analysis demonstrated net benefit of InterpretabNet compared with treat-all, treat-none, and benchmark models across clinically relevant thresholds.Conclusions: InterpretabNet provides accurate, externally validated, and interpretable predictions for MINS and POAF using routinely available perioperative data. Risk factors were similar for each endpoint, with some being potentially modifiable.
- 12 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessInterpretable Deep Learning for Comprehensive Cardiac Risk Stratification after Esophageal Cancer Surgery: Development and External Validation of the InterpretabNet Model for Myocardial Injury and New-Onset Atrial Fibrillation
Background: Myocardial injury after non-cardiac surgery (MINS) and new-onset postoperative atrial fibrillation (POAF) are common and serious complications. We developed and externally validated an interpretable machine-learning platform (InterpretabNet) to predict MINS and POAF in patients recovering oesophageal cancer surgery.Methods: We retrospectively included 3,573 adults who underwent elective oesophagectomy for oesophageal cancer at Zhongshan Hospital, Fudan University, Shanghai, China, between 1 January 2015 and 30 June 2025. The cohort was divided using a fixed stratified 80:20 split into a training cohort of 2,858 patients and an internal validation cohort of 715 patients. External validation was performed in 638 eligible patients from the INSPIRE database, comprising patients treated at Seoul National University Hospital, Seoul, Republic of Korea, between 2011 and 2020. MINS was defined as an ischaemic postoperative cardiac troponin elevation above the assay-specific 99th-percentile upper reference limit occurring within the first 72 h after surgery. New-onset POAF was defined as an atrial fibrillation episode lasting ≥30 s or requiring treatment and detected during the first 7 postoperative days or until hospital discharge, whichever occurred first. InterpretabNet was compared with extreme gradient boosting, random forest, support vector machine, decision tree, and penalised logistic regression.ResultsPOAF was observed in 28% of the patients in the derivation cohort, and MINS in 30%. Interpretation: Net showed high discrimination in internal validation (POAF AUC 0.933 [95%CI: 0.916-0.951]; MINS AUC 0.933 [95%CI: 0.916-0.951]) and in the external cohort (POAF AUC 0.939 [95%CI: 0.922-0.956]; MINS AUC 0.936 [95%CI: 0.917-0.955]), with balanced sensitivity and specificity and good calibration. SHAP analyses identified similar risk factors for both endpoints, dominated by age, hypertension, diabetes, BMI, obstructive sleep apnoea, pre-operative haemoglobin, surgical duration, inflammatory markers, and blood loss. Decision-curve analysis demonstrated net benefit of InterpretabNet compared with treat-all, treat-none, and benchmark models across clinically relevant thresholds.Conclusions: InterpretabNet provides accurate, externally validated, and interpretable predictions for MINS and POAF using routinely available perioperative data. Risk factors were similar for each endpoint, with some being potentially modifiable.
- Open Access
- 15 July 2026
- Published by Elsevier in SSRN Electronic Journal
Comparing Subcostal Transversus Abdominis Plane Block With Rectus Sheath Block Versus Thoracic Epidural Block on Recovery Quality after Ambulatory Laparoscopic Cholecystectomy: A Randomised Controlled Trial
Background: Effective analgesia is essential for enhanced recovery after ambulatory laparoscopic cholecystectomy (LC). We aimed to test whether thoracic epidural block (TEB) provides superior 24-h recovery quality compared with subcostal transversus abdominis plane block combined with rectus sheath block (TAP plus RSB) in patients undergoing ambulatory single-incision LC under general anaesthesia. Methods: In this single-centre, randomised, double-blind trial conducted in China, 128 adult patients scheduled for elective ambulatory single-incision LC were assigned 1:1 to TEB (n = 64) or TAP Plus RSB (n = 64), both with standardised general anaesthesia and multimodal analgesia. The primary outcome was the Quality of Recovery-15 (QoR-15) score at 24 h postoperatively, assessed in the intention-to-treat population. The trial is registered at ChiCTR (ChiCTR2500109393). Findings: Between September 2025 and March 2026, all 128 patients completed the study. At 24 h, median QoR-15 scores were higher with TEB than with TAP Plus RSB (135.0 [IQR 131.0–138.3] vs. 129.0 [124.8–132.0]; adjusted mean difference 6.4 [95% CI 4.49–8.37]; P < 0.001), exceeding the minimal clinically important difference. This difference was not significant at 48 h. TEB reduced opioid consumption (median 0.04 vs 37.73 mg oral morphine equivalents; P < 0.001), shortened time to first flatus (6.2 vs 10.0 h; P < 0.001), and lowered the incidence of postoperative nausea and vomiting (9.4% vs 26.6%; P = 0.011). Time to discharge readiness was shorter (mean difference −0.62 h; P = 0.027). No block-related complications occurred with either technique. Interpretation: In patients undergoing ambulatory single-incision LC, TEB provided superior 24-h recovery quality and clinically meaningful opioid-sparing effects compared with TAP Plus RSB, without an increase in adverse events. These findings support the use of epidural analgesia for ambulatory biliary surgery, particularly for patients at high risk of opioid-related adverse events.
- 15 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessComparing Subcostal Transversus Abdominis Plane Block With Rectus Sheath Block Versus Thoracic Epidural Block on Recovery Quality after Ambulatory Laparoscopic Cholecystectomy: A Randomised Controlled Trial
Background: Effective analgesia is essential for enhanced recovery after ambulatory laparoscopic cholecystectomy (LC). We aimed to test whether thoracic epidural block (TEB) provides superior 24-h recovery quality compared with subcostal transversus abdominis plane block combined with rectus sheath block (TAP plus RSB) in patients undergoing ambulatory single-incision LC under general anaesthesia. Methods: In this single-centre, randomised, double-blind trial conducted in China, 128 adult patients scheduled for elective ambulatory single-incision LC were assigned 1:1 to TEB (n = 64) or TAP Plus RSB (n = 64), both with standardised general anaesthesia and multimodal analgesia. The primary outcome was the Quality of Recovery-15 (QoR-15) score at 24 h postoperatively, assessed in the intention-to-treat population. The trial is registered at ChiCTR (ChiCTR2500109393). Findings: Between September 2025 and March 2026, all 128 patients completed the study. At 24 h, median QoR-15 scores were higher with TEB than with TAP Plus RSB (135.0 [IQR 131.0–138.3] vs. 129.0 [124.8–132.0]; adjusted mean difference 6.4 [95% CI 4.49–8.37]; P < 0.001), exceeding the minimal clinically important difference. This difference was not significant at 48 h. TEB reduced opioid consumption (median 0.04 vs 37.73 mg oral morphine equivalents; P < 0.001), shortened time to first flatus (6.2 vs 10.0 h; P < 0.001), and lowered the incidence of postoperative nausea and vomiting (9.4% vs 26.6%; P = 0.011). Time to discharge readiness was shorter (mean difference −0.62 h; P = 0.027). No block-related complications occurred with either technique. Interpretation: In patients undergoing ambulatory single-incision LC, TEB provided superior 24-h recovery quality and clinically meaningful opioid-sparing effects compared with TAP Plus RSB, without an increase in adverse events. These findings support the use of epidural analgesia for ambulatory biliary surgery, particularly for patients at high risk of opioid-related adverse events.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Comparison of the Efficacy of Ciprofol and Propofol for Rapid Sequence Induction and Intubation in Elective Non-Cardiac Surgery: A Prospective, Randomized, Non-Inferiority Trial
Background: Rapid sequence induction and intubation (RSII) requires an agent that provides excellent intubating conditions with minimal hemodynamic disturbance. Propofol is standard but often causes hypotension. We compared the novel agent ciprofol with propofol for RSII in adult patients scheduled for elective non-cardiac surgery. Methods: In this prospective, randomized, double-blind, non-inferiority trial, 170 adult patients scheduled for elective non-cardiac surgery were allocated to receive intravenous ciprofol (0.4 mg/kg, n = 85) or propofol (2.0 mg/kg, n = 85) for induction, with remifentanil and rocuronium. The non-inferiority margin was set at – 10% for the primary outcome. The primary outcome was the proportion of patients with excellent intubation conditions (Viby-Mogensen scale). Secondary outcomes included incidence of hypotension, induction success rate, time to loss of consciousness (LOC), bispectral index (BIS) values, and pain on injection. Results: Excellent intubation conditions were achieved in 96.5% (82/85) of the ciprofol group and 95.3% (81/85) of the propofol group (difference 1.2%, 95% CI: – 4.4% to 6.7%). The lower limit of the 95% CI exceeded the prespecified non-inferiority margin of – 10%. The per-protocol analysis confirmed non-inferiority (difference 1.2%, 95% CI – 4.2% to 6.7%). The incidence of post-induction hypotension was significantly lower in the ciprofol group (15.3% vs 43.5%; RR 0.35, 95% CI 0.20 to 0.61; P < 0.001). No patient reported injection pain with ciprofol, compared to 68.2% with propofol (P < 0.001). Time to LOC and induction success rates were similar between groups. Conclusion: In adult patients undergoing elective non-cardiac surgery under a standardized RSI protocol, ciprofol 0.4 mg/kg provided intubating conditions non-inferior to propofol 2.0 mg/kg and was associated with less post-induction hypotension and injection pain. Further studies are needed in emergency, critically ill, and high-risk RSI populations. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2500095742).
- 1 July 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Open AccessComparison of the Efficacy of Ciprofol and Propofol for Rapid Sequence Induction and Intubation in Elective Non-Cardiac Surgery: A Prospective, Randomized, Non-Inferiority Trial
Background: Rapid sequence induction and intubation (RSII) requires an agent that provides excellent intubating conditions with minimal hemodynamic disturbance. Propofol is standard but often causes hypotension. We compared the novel agent ciprofol with propofol for RSII in adult patients scheduled for elective non-cardiac surgery. Methods: In this prospective, randomized, double-blind, non-inferiority trial, 170 adult patients scheduled for elective non-cardiac surgery were allocated to receive intravenous ciprofol (0.4 mg/kg, n = 85) or propofol (2.0 mg/kg, n = 85) for induction, with remifentanil and rocuronium. The non-inferiority margin was set at – 10% for the primary outcome. The primary outcome was the proportion of patients with excellent intubation conditions (Viby-Mogensen scale). Secondary outcomes included incidence of hypotension, induction success rate, time to loss of consciousness (LOC), bispectral index (BIS) values, and pain on injection. Results: Excellent intubation conditions were achieved in 96.5% (82/85) of the ciprofol group and 95.3% (81/85) of the propofol group (difference 1.2%, 95% CI: – 4.4% to 6.7%). The lower limit of the 95% CI exceeded the prespecified non-inferiority margin of – 10%. The per-protocol analysis confirmed non-inferiority (difference 1.2%, 95% CI – 4.2% to 6.7%). The incidence of post-induction hypotension was significantly lower in the ciprofol group (15.3% vs 43.5%; RR 0.35, 95% CI 0.20 to 0.61; P < 0.001). No patient reported injection pain with ciprofol, compared to 68.2% with propofol (P < 0.001). Time to LOC and induction success rates were similar between groups. Conclusion: In adult patients undergoing elective non-cardiac surgery under a standardized RSI protocol, ciprofol 0.4 mg/kg provided intubating conditions non-inferior to propofol 2.0 mg/kg and was associated with less post-induction hypotension and injection pain. Further studies are needed in emergency, critically ill, and high-risk RSI populations. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2500095742).
- Open Access
- 29 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Mesenchymal stromal cells alleviate neuropathic pain in association with M2 macrophage polarization in dorsal root ganglia and peripheral nerve repair
Neuropathic pain (NP) is a debilitating condition with limited effective treatments. Mesenchymal stromal cells (MSCs) have emerged as a potential therapeutic strategy due to their immunomodulatory properties. This study investigated whether intravenous administration of human umbilical cord-derived MSCs could alleviate NP in a rat chronic constriction injury (CCI) model and explored the associated changes in macrophage polarization and nerve structure. Male Sprague Dawley rats were subjected to CCI of the sciatic nerve and randomly divided into Control, CCI, and CCI+MSCs groups (n = 10/group). The CCI+MSCs group received 1 × 10⁶ MSCs via tail vein injection on postoperative day 7. Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were assessed at baseline and on postoperative days 1, 3, 5, 7, 10, and 15. On day 15, dorsal root ganglia (DRG) were collected for immunofluorescence staining of CD68 (pan-macrophage marker) and CD206 (M2 marker), and sciatic nerves were examined by hematoxylin-eosin staining and transmission electron microscopy (TEM). CCI induced significant mechanical and thermal hypersensitivity from postoperative day 7 through day 15 (p < 0.05 vs. Control). MSC administration partially restored MWT and TWL values compared with the CCI group (p < 0.05). Immunofluorescence revealed increased CD68⁺ macrophage infiltration in the DRG of CCI rats, which was attenuated by MSC treatment. Concurrently, CD206 expression was enhanced in the CCI+MSCs group, suggesting a shift toward an M2-like macrophage phenotype. Histological and ultrastructural analyses showed that MSC treatment was associated with reduced inflammatory cell infiltration, increased Schwann cell counts, lower G-ratio, and improved myelin sheath integrity compared with the untreated CCI group (p < 0.05). Intravenous MSC administration was associated with attenuation of nociceptive hypersensitivity, enhanced M2-like macrophage polarization in the DRG, and partial structural repair of the injured sciatic nerve in a rat CCI model. These findings suggest that MSCs may represent a promising cell-based approach for NP treatment, although further studies are needed to establish causal mechanisms and evaluate long-term safety and efficacy.
- 29 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessMesenchymal stromal cells alleviate neuropathic pain in association with M2 macrophage polarization in dorsal root ganglia and peripheral nerve repair
Neuropathic pain (NP) is a debilitating condition with limited effective treatments. Mesenchymal stromal cells (MSCs) have emerged as a potential therapeutic strategy due to their immunomodulatory properties. This study investigated whether intravenous administration of human umbilical cord-derived MSCs could alleviate NP in a rat chronic constriction injury (CCI) model and explored the associated changes in macrophage polarization and nerve structure. Male Sprague Dawley rats were subjected to CCI of the sciatic nerve and randomly divided into Control, CCI, and CCI+MSCs groups (n = 10/group). The CCI+MSCs group received 1 × 10⁶ MSCs via tail vein injection on postoperative day 7. Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were assessed at baseline and on postoperative days 1, 3, 5, 7, 10, and 15. On day 15, dorsal root ganglia (DRG) were collected for immunofluorescence staining of CD68 (pan-macrophage marker) and CD206 (M2 marker), and sciatic nerves were examined by hematoxylin-eosin staining and transmission electron microscopy (TEM). CCI induced significant mechanical and thermal hypersensitivity from postoperative day 7 through day 15 (p < 0.05 vs. Control). MSC administration partially restored MWT and TWL values compared with the CCI group (p < 0.05). Immunofluorescence revealed increased CD68⁺ macrophage infiltration in the DRG of CCI rats, which was attenuated by MSC treatment. Concurrently, CD206 expression was enhanced in the CCI+MSCs group, suggesting a shift toward an M2-like macrophage phenotype. Histological and ultrastructural analyses showed that MSC treatment was associated with reduced inflammatory cell infiltration, increased Schwann cell counts, lower G-ratio, and improved myelin sheath integrity compared with the untreated CCI group (p < 0.05). Intravenous MSC administration was associated with attenuation of nociceptive hypersensitivity, enhanced M2-like macrophage polarization in the DRG, and partial structural repair of the injured sciatic nerve in a rat CCI model. These findings suggest that MSCs may represent a promising cell-based approach for NP treatment, although further studies are needed to establish causal mechanisms and evaluate long-term safety and efficacy.
- 14 May 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 112, 112234
Dynamic assessment of gastric emptying patterns after endoscopic bowel preparation using ultrasonography: A prospective observational study
- 14 May 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 112, 112234
Dynamic assessment of gastric emptying patterns after endoscopic bowel preparation using ultrasonography: A prospective observational study
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
A Novel Standardized Dexmedetomidine Nasal Spray Formulation for Procedural Sedation During Venous Port Implantation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Noninvasive sedative approaches are increasingly valued in ambulatory anesthesia. The aim of this study was to evaluate the efficacy and safety of the novel standardized dexmedetomidine nasal spray for procedural sedation in adult patients undergoing port implantation under local anesthesia. Eighty-two patients undergoing port implantation under local anesthesia were enrolled in this study. The patients were randomly allocated to receive nasal spray with 100μg dexmedetomidine or placebo with saline, 30 min prior to the procedure. The primary outcome was the postoperative anesthesia satisfaction assessed using Iowa Satisfaction with Anesthesia Scale (ISAS; 11-item mean score, −3 to +3). The secondary outcomes included the Ramsay sedation scale (RSS), visual analog scale (VAS), postoperative sleep quality, hemodynamic changes, and the incidence of adverse events. Compared with placebo, dexmedetomidine significantly improved satisfaction with procedure (ISAS median [IQR] was 2.7 [2.5–2.8] vs 2.1 [1.8–2.4]; P<0.001), indicating a clinically relevant improvement in patient experience during outpatient port implantation under local anesthesia, and postoperative sleep quality (4.4±0.8 vs 3.1±0.8, P<0.001) during the first postoperative night. The incidence of adverse events and other secondary outcomes were comparable between the two groups. A standardized dexmedetomidine nasal spray provided reliable, well-tolerated sedation, enhanced postoperative comfort, and improved postoperative sleep quality in adults undergoing minor procedures under local anesthesia. These findings support its feasibility as a noninvasive option for outpatient procedural sedation.
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessA Novel Standardized Dexmedetomidine Nasal Spray Formulation for Procedural Sedation During Venous Port Implantation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Noninvasive sedative approaches are increasingly valued in ambulatory anesthesia. The aim of this study was to evaluate the efficacy and safety of the novel standardized dexmedetomidine nasal spray for procedural sedation in adult patients undergoing port implantation under local anesthesia. Eighty-two patients undergoing port implantation under local anesthesia were enrolled in this study. The patients were randomly allocated to receive nasal spray with 100μg dexmedetomidine or placebo with saline, 30 min prior to the procedure. The primary outcome was the postoperative anesthesia satisfaction assessed using Iowa Satisfaction with Anesthesia Scale (ISAS; 11-item mean score, −3 to +3). The secondary outcomes included the Ramsay sedation scale (RSS), visual analog scale (VAS), postoperative sleep quality, hemodynamic changes, and the incidence of adverse events. Compared with placebo, dexmedetomidine significantly improved satisfaction with procedure (ISAS median [IQR] was 2.7 [2.5–2.8] vs 2.1 [1.8–2.4]; P<0.001), indicating a clinically relevant improvement in patient experience during outpatient port implantation under local anesthesia, and postoperative sleep quality (4.4±0.8 vs 3.1±0.8, P<0.001) during the first postoperative night. The incidence of adverse events and other secondary outcomes were comparable between the two groups. A standardized dexmedetomidine nasal spray provided reliable, well-tolerated sedation, enhanced postoperative comfort, and improved postoperative sleep quality in adults undergoing minor procedures under local anesthesia. These findings support its feasibility as a noninvasive option for outpatient procedural sedation.
- 15 March 2026
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 40 (8) , 2481-2488
Comparative Effectiveness of Anesthesia Techniques on the Duration of Endovascular Lower-Extremity Revascularization: A Single-CenterRetrospective Study
- 15 March 2026
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 40 (8) , 2481-2488
Comparative Effectiveness of Anesthesia Techniques on the Duration of Endovascular Lower-Extremity Revascularization: A Single-CenterRetrospective Study
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (2) , 127
Effect of epidural analgesia on the neutrophil-to-lymphocyte ratio after thoracic surgery: a large-scale retrospective cohort study
Background: Postoperative analgesia is crucial for recovery after thoracic surgery. The neutrophil-to-lymphocyte ratio (NLR) serves as an indicator of systemic inflammatory status. This study aimed to evaluate the impact of different postoperative analgesia modalities on NLR and recovery outcomes in patients undergoing thoracic surgery. Methods: We retrospectively analyzed data from 1,099 patients who underwent thoracic surgery between January 2020 and July 2024 and received patient-controlled analgesia (PCA). Based on the pain relief method employed, the patients were categorized into two groups: the patient-controlled epidural analgesia (PCEA) group (n=533) and the patient-controlled intravenous analgesia (PCIA) group (n=566). The primary outcome was the NLR at 48 hours postoperatively. Secondary outcomes included postoperative pain scores and recovery parameters. Results: The postoperative NLR at 48 hours was significantly lower in the PCEA group (4.75) than in the PCIA group (5.90) (PConclusions: Compared to intravenous analgesia, epidural analgesia significantly reduces the postoperative NLR.
- 1 February 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (2) , 127
Open AccessEffect of epidural analgesia on the neutrophil-to-lymphocyte ratio after thoracic surgery: a large-scale retrospective cohort study
Background: Postoperative analgesia is crucial for recovery after thoracic surgery. The neutrophil-to-lymphocyte ratio (NLR) serves as an indicator of systemic inflammatory status. This study aimed to evaluate the impact of different postoperative analgesia modalities on NLR and recovery outcomes in patients undergoing thoracic surgery. Methods: We retrospectively analyzed data from 1,099 patients who underwent thoracic surgery between January 2020 and July 2024 and received patient-controlled analgesia (PCA). Based on the pain relief method employed, the patients were categorized into two groups: the patient-controlled epidural analgesia (PCEA) group (n=533) and the patient-controlled intravenous analgesia (PCIA) group (n=566). The primary outcome was the NLR at 48 hours postoperatively. Secondary outcomes included postoperative pain scores and recovery parameters. Results: The postoperative NLR at 48 hours was significantly lower in the PCEA group (4.75) than in the PCIA group (5.90) (PConclusions: Compared to intravenous analgesia, epidural analgesia significantly reduces the postoperative NLR.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Comparison of the Effects of Glycopyrrolate and Atropine on Postoperative Delirium in Older Adult Patients Undergoing Laparoscopic Colorectal Surgery: A Randomized Controlled Trial
Background: Postoperative delirium (POD) is a common complication that hinders recovery in older patients. This study aimed to compare the effects of glycopyrrolate and atropine, used to counteract the peripheral effects of neostigmine, on POD incidence in older patients undergoing laparoscopic colorectal surgery. Methods: This single-centre, double-blind, randomized controlled trial recruited patients (aged 65-80 years) undergoing laparoscopic colorectal surgery. Patients were randomized to receive either glycopyrrolate (0.04 mg kg-1 neostigmine and 0.008 mg kg-1 glycopyrrolate) or atropine (0.04 mg kg-1 neostigmine and 0.016 mg kg-1 atropine) during emergence from anaesthesia. The primary outcome was the incidence of POD within the first 3 postoperative days, assessed using the 3-minute Diagnostic Interview for Confusion Assessment Method. Secondary outcomes included comparing the hemodynamic effects of glycopyrrolate and atropine and examining POD biomarkers. Results: Among 121 patients, the glycopyrrolate group had a significantly lower incidence of POD compared with the atropine group (11.7% vs 27.9%; relative risk, 0.42; 95% confidence interval, 0.19-0.94; p = 0.045). Glycopyrrolate better maintained baseline heart rate and mean arterial pressure. No significant differences were observed in plasma levels of neurofilament light chain, neuron-specific enolase, and Tau protein between groups at different time points. Conclusion: The combination of glycopyrrolate and neostigmine was associated with a lower incidence of POD than atropine in older adults undergoing laparoscopic colorectal surgery.
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessComparison of the Effects of Glycopyrrolate and Atropine on Postoperative Delirium in Older Adult Patients Undergoing Laparoscopic Colorectal Surgery: A Randomized Controlled Trial
Background: Postoperative delirium (POD) is a common complication that hinders recovery in older patients. This study aimed to compare the effects of glycopyrrolate and atropine, used to counteract the peripheral effects of neostigmine, on POD incidence in older patients undergoing laparoscopic colorectal surgery. Methods: This single-centre, double-blind, randomized controlled trial recruited patients (aged 65-80 years) undergoing laparoscopic colorectal surgery. Patients were randomized to receive either glycopyrrolate (0.04 mg kg-1 neostigmine and 0.008 mg kg-1 glycopyrrolate) or atropine (0.04 mg kg-1 neostigmine and 0.016 mg kg-1 atropine) during emergence from anaesthesia. The primary outcome was the incidence of POD within the first 3 postoperative days, assessed using the 3-minute Diagnostic Interview for Confusion Assessment Method. Secondary outcomes included comparing the hemodynamic effects of glycopyrrolate and atropine and examining POD biomarkers. Results: Among 121 patients, the glycopyrrolate group had a significantly lower incidence of POD compared with the atropine group (11.7% vs 27.9%; relative risk, 0.42; 95% confidence interval, 0.19-0.94; p = 0.045). Glycopyrrolate better maintained baseline heart rate and mean arterial pressure. No significant differences were observed in plasma levels of neurofilament light chain, neuron-specific enolase, and Tau protein between groups at different time points. Conclusion: The combination of glycopyrrolate and neostigmine was associated with a lower incidence of POD than atropine in older adults undergoing laparoscopic colorectal surgery.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-10
Comparative Effectiveness of Single-Dose Epidural Esketamine versus Hydromorphone in Thoracic and Upper Abdominal Surgery: A Randomized Trial
This study aimed to evaluate the effectiveness of a single epidural dose of esketamine versus hydromorphone in patients undergoing abdominal and thoracic surgeries. Patients undergoing elective abdominal and thoracic surgery were randomly assigned to receive either a single epidural injection of 15 mg esketamine (Group E) or 0.5 mg hydromorphone (Group H) at the end of surgery. All patients received intravenous patient-controlled analgesia postoperatively. The primary outcome was hydromorphone consumption within 48 hours after surgery. Secondary outcomes included time to first rescue analgesia, hydromorphone consumption within 0–24, 24–48, and 48–72 hours, numerical rating scale (NRS) pain scores, postoperative recovery scores, and complications. In total, 205 patients were enrolled, with 186 randomly assigned to either group E (n = 93) or group H (n = 93). Hydromorphone consumption within 48 hours postoperatively was significantly higher in group E than in group H. The time to first rescue analgesia was significantly longer in group H compared to group E. Within the first 24 hours postoperatively, patients in group E required more hydromorphone than those in group H. No significant difference in hydromorphone consumption between the two groups at 24–48 and 48–72 hours postoperatively. The NRS scores during movement were significantly higher in group E than in group H at 3 and 6 hours postoperatively. Single-dose epidural esketamine for postoperative analgesia resulted in higher hydromorphone consumption and a shorter time to first rescue analgesia compared to hydromorphone.
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-10
Open AccessComparative Effectiveness of Single-Dose Epidural Esketamine versus Hydromorphone in Thoracic and Upper Abdominal Surgery: A Randomized Trial
This study aimed to evaluate the effectiveness of a single epidural dose of esketamine versus hydromorphone in patients undergoing abdominal and thoracic surgeries. Patients undergoing elective abdominal and thoracic surgery were randomly assigned to receive either a single epidural injection of 15 mg esketamine (Group E) or 0.5 mg hydromorphone (Group H) at the end of surgery. All patients received intravenous patient-controlled analgesia postoperatively. The primary outcome was hydromorphone consumption within 48 hours after surgery. Secondary outcomes included time to first rescue analgesia, hydromorphone consumption within 0–24, 24–48, and 48–72 hours, numerical rating scale (NRS) pain scores, postoperative recovery scores, and complications. In total, 205 patients were enrolled, with 186 randomly assigned to either group E (n = 93) or group H (n = 93). Hydromorphone consumption within 48 hours postoperatively was significantly higher in group E than in group H. The time to first rescue analgesia was significantly longer in group H compared to group E. Within the first 24 hours postoperatively, patients in group E required more hydromorphone than those in group H. No significant difference in hydromorphone consumption between the two groups at 24–48 and 48–72 hours postoperatively. The NRS scores during movement were significantly higher in group E than in group H at 3 and 6 hours postoperatively. Single-dose epidural esketamine for postoperative analgesia resulted in higher hydromorphone consumption and a shorter time to first rescue analgesia compared to hydromorphone.